Article
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
Blood advances - 12 Sept 2023
Johnson William T, Ganesan Nivetha, Epstein-Peterson Zachary D, Moskowitz Alison J, Stuver Robert N, Maccaro Catherine R, Galasso Natasha, Chang Tiffany, Khan Niloufer, Aypar Umut, Lewis Natasha E, Zelenetz Andrew D, Palomba M Lia, Matasar Matthew J, Noy Ariela, Hamilton Audrey M, Hamlin Paul, Caron Philip C, Straus David J, Intlekofer Andrew M, Lee Batlevi Connie, Kumar Anita, Owens Colette N, Sauter Craig S, Falchi Lorenzo, Lue Jennifer K, Vardhana Santosha A, Salles Gilles, Dogan Ahmet, Schultz Nikolaus D, Arcila Maria E, Horwitz Steven M
Abstract excerpt
Nodal peripheral T-cell lymphomas (PTCL), the most common PTCLs, are generally treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based curative-intent chemotherapy. Recent molecular data have assisted in prognosticating these PTCLs, but most reports lack detailed baseline clinical characteristics and treatment courses. We retrospectively evaluated cases of PTCL treated with CHOP-based...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.